CD47 and neoplasm: Macrophage-based therapies represent a novel frontier in cellular immunotherapy for PROC, with CAR-M, CD47 blockade, and CSF1R inhibition offering complementary strategies to reprogram or enhance macrophage anti-tumor activity.